NEWTOWN, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In a recently published phase 3 trial, credit card-sized cultured skin grafts corrected for the COL7A1 mutation that causes recessive dystrophic epidermolysis bullosa (RDEB) and enabled most patients ...
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), which is under review for ...
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma”, "Traws” or "the Company”), a clinical-stage biopharmaceutical company developing novel therapies to ...
EXTON, Pa. (WPVI) -- A Chester County biotech firm now has the FDA's OK to begin pediatric tests on its breakthrough drug. It could ease suffering for thousands with a devastating skin disorder known ...
CORDStrom supply chain -- A new expanded material transfer agreement with Anthony Nolan U.K. Cord Blood Bank secures long-term umbilical cord supply for commercial manufacturing. XPro development -- ...
CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin’) ...
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results